Zobrazeno 1 - 4
of 4
pro vyhledávání: '"François Ciza"'
Autor:
Valérie Schwœbel, Arnaud Trébucq, Zacharie Kashongwe, Alimata S. Bakayoko, Christopher Kuaban, Juergen Noeske, Souleymane H. Harouna, Mahamadou B. Souleymane, Alberto Piubello, François Ciza, Valentin Fikouma, Michel Gasana, Martial Ouedraogo, Martin Gninafon, Armand Van Deun, Elisa Tagliani, Daniela M. Cirillo, Kobto G. Koura, Hans L. Rieder
Publikováno v:
EClinicalMedicine, Vol 20, Iss , Pp - (2020)
Background: Treatment outcomes of the shorter regimen for rifampicin-resistant tuberculosis are not completely established. We report on these outcomes two years after treatment completion among patients enrolled in an observational cohort study in n
Externí odkaz:
https://doaj.org/article/5ef7adc6d97a49b6a696aab540072424
Autor:
Arnaud Trébucq, Mahamadou Bassirou Souleymane, Michel Gasana, Alberto Piubello, Valentin Fikouma, Elisa Tagliani, François Ciza, Zacharie Kashongwe, Armand Van Deun, Valérie Schwœbel, K G Koura, Hans L. Rieder, Martial Ouedraogo, M. Gninafon, Juergen Noeske, Daniela Maria Cirillo, Alimata S. Bakayoko, Christopher Kuaban, Souleymane H. Harouna
Publikováno v:
EClinicalMedicine, Vol 20, Iss, Pp-(2020)
EClinicalMedicine
EClinicalMedicine
Background: Treatment outcomes of the shorter regimen for rifampicin-resistant tuberculosis are not completely established. We report on these outcomes two years after treatment completion among patients enrolled in an observational cohort study in n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b44aa65d164b30a24c19b25b043bd8
http://www.sciencedirect.com/science/article/pii/S2589537020300122
http://www.sciencedirect.com/science/article/pii/S2589537020300122
Autor:
Alberto Roggi, Nimer Ortuno-Gutierrez, Alberto Piubello, François Ciza, Tinne Gils, Tom Decroo, Michel Sawadogo
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 6
Journal of Clinical Medicine, Vol 9, Iss 1873, p 1873 (2020)
Volume 9
Issue 6
Journal of Clinical Medicine, Vol 9, Iss 1873, p 1873 (2020)
The introduction of the nine-month short-treatment regimen (STR) has drastically improved outcomes of rifampicin-resistant tuberculosis (RR-TB) treatment. Adverse events (AE) commonly occur, including injectable-induced hearing loss. In Burundi we re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25e120860e878ca5c6f72c3f9040e4ca
https://doi.org/10.3390/jcm9061873
https://doi.org/10.3390/jcm9061873
Autor:
S Hassane, M. Gninafon, A Bakayoko, K G Koura, J Noeske, Hans L. Rieder, Daniela Maria Cirillo, Mathieu Ouédraogo, A. Van Deun, Christopher Kuaban, V Fikouma, Z Kashongwe, Arnaud Trébucq, Alberto Piubello, V Schwoebel, François Ciza, B Souleymane, M Gasana
Publikováno v:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 22(1)
Setting Nine countries in West and Central Africa. Objective To assess outcomes and adverse drug events of a standardised 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB) among patients never previously treated with second-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bedeb10be7e5e7863e2c50dd5d2f8687
https://pubmed.ncbi.nlm.nih.gov/29297416
https://pubmed.ncbi.nlm.nih.gov/29297416